

EVALUATION OF THE TOLERANCE OF A FOAMING GEL CLEANSER BY SUBJECTS WITH STAGE I HIDRADENITIS SUPPURATIVA

HELENA POLENA¹, BENOÎT CADARS¹, FLORIANE MONTU¹, JESSICA ASGARPOUR², MARISA PONZO³, HÉLÈNE VEILLETTE⁴, LAUREN LAM⁵, MAXIME LIGOT⁶, ELODIE PRESTAT-MARQUIS¹

¹NAOS (BIODERMA), Aix-en-Provence, France, ²University of Toronto, Division of Dermatology, Toronto, ON, Canada, ³North York Dermatology Clinic, North York, ON, Canada, ⁴CHU de Quebec-Université Laval, Division of Dermatology, Dept of Internal Medicine, Quebec, Québec, Canada, ⁵Canadian Hidradenitis Suppurativa Foundation, ⁶NAOS Canada, Montréal, Canada


INTRODUCTION

Hidradenitis Suppurative (HS), also known as acne inversa, is a chronic, recurrent, inflammatory and painful skin condition affecting apocrine gland-rich areas (especially axillae, inguinal and anogenital regions)¹. Clinically diagnosed through painful nodules that may progress to abscesses, sinus tracts and scars, HS is staged by Hurley classification²:

Stage	Clinical description
Stage I	Single or multiple abscesses without tracts/scarring
Stage II	Recurrent abscesses with separated tracts/scarring
Stage III	Diffuse/interconnected involvement of tracts and abscesses

Despite underdiagnosis due to delays and stigma, HS severely impairs quality of life via pain, discharge, odor, anxiety, and social isolation³. Therefore, daily management requires a multidisciplinary approach tailored to disease severity that combines medical, surgical, and psychological care. In this context, the present study was designed to evaluate the tolerance of a **foaming gel cleanser** in patients with stage I HS.


MATERIALS & METHODS




*48 subjects completed the study and were analyzed

RESULTS


Graph 1: Subjective efficacy assessment at Day 21



Graph 3: Future use assessment at Day 21



Graph 2: Cosmetic qualities assessment at Day 21



In this inclusive study, among the 48 participants who completed the study, the foaming gel cleanser demonstrated excellent tolerance (98%) after 21 days of use, with one mild adverse event reported only, and provided beneficial effects on HS symptoms. By D21, 90% of subjects reported a purified and cleansed skin feeling, 73% described their skin as soothed and comfortable, and 67% noted improved suppleness and softness. Given that HS is characterized by unpredictable flares that can significantly impair quality of life, it is notable that 54% of participants reported reduced lesion inflammation and 51% experienced decreased skin pain (Graph 1).

The gel's galenic formulation proved well suited to this diverse population, with 100% of participants appreciating its appearance, 98% its texture, 92% its ease of use, and 90% its scent, which are factors that support strong adherence in a condition prone to recurrent flares (Graph 2).

User satisfaction was consistently high: 90% of subjects expressed overall satisfaction, 84% indicated willingness to continue use after the study, and 88% would recommend it to other individuals with HS (Graph 3).

CONCLUSION

The foaming gel cleanser demonstrated an excellent tolerance and efficacy in diverse stage I HS patients after 21 days of use. The product provided significant symptom relief during unpredictable flares with direct improvements in quality of life, **body comfort and disease-related insecurities**. High subject satisfaction reflected the formulation's seamless adaptation to this type of population. Overall, these findings in a small cohort confirm the value of the foaming gel cleanser as an inclusive, well-tolerated dermocosmetic for managing mild HS flares and enhancing patient well-being.

¹Sabat, R.; Jemec, G. B. E.; Matusiak, L.; Kimball, A. B.; Prens, E.; Wolk, K. Hidradenitis Suppurativa. *Nat. Rev. Dis. Primers* 2020, 6, 18.

²Hurley, H. J. Axillary Hyperhidrosis, Apocrine Bromhidrosis, Hidradenitis Suppurativa and Familial Benign Pemphigus. In *Surgical Approach*; Marcel Dekker Inc.: New York, 1996; pp 623-645.

³Krajewski, P. K.; Matusiak, L.; von Stebut, E.; et al. Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients. *Life* 2021, 11, 34.